Brady Collins
The development of a coronavirus vaccine has been a highly anticipated event, with several companies vying to be the first to gain approval from the FDA. In December 2020, the FDA approved Pfizer and BioNTech's coronavirus vaccine for emergency use, with Moderna's vaccine following suit. The approval came after intense pressure from the Trump administration, with President Trump accusing the FDA of intentionally slowing down the process. The vaccine was recommended to be distributed first to healthcare workers and residents and staff of long-term care facilities.
| Characteristics | Values |
|---|---|
| Date of approval | 11 December 2020 |
| Vaccine name | Pfizer-BioNTech COVID-19 vaccine |
| Type of approval | Emergency Use Authorization (EUA) |
| Manufacturer | Pfizer |
| Vaccine type | mRNA vaccine |
| Active ingredient | Tozinameran |
| Countries with approval | Many countries and the European Union |
| Other approvals | EUA for Moderna vaccine on 18 December 2020 |
| Latest updates | FDA approved updated mRNA COVID-19 vaccines in August 2024 |
| Novavax vaccine | Approved for use in individuals 12 years and older |
| Underwent FDA scrutiny in April 2025 |
Explore related products
What You'll Learn
- The FDA approved the Pfizer-BioNTech COVID-19 vaccine in 2020
- The Moderna vaccine was granted EUA approval by the FDA in 2020
- The FDA approved updated COVID-19 vaccines in 2024
- The Novavax COVID-19 vaccine was approved by the FDA in 2024
- The FDA might not renew the EUA for Pfizer's COVID-19 vaccine for young kids
The FDA approved the Pfizer-BioNTech COVID-19 vaccine in 2020
The US Food and Drug Administration (FDA) approved the Pfizer-BioNTech COVID-19 vaccine in 2020. The Pfizer-BioNTech vaccine was one of the first COVID-19 vaccines to be approved by the FDA and was granted Emergency Use Authorization (EUA) by the FDA in May 2020 for individuals 16 years of age and older. The vaccine was found to be 95% effective in preventing COVID-19 infection in clinical trials.
The Pfizer-BioNTech COVID-19 vaccine is an mRNA vaccine, which means it contains genetic material that teaches our cells to produce a protein that triggers an immune response to protect against COVID-19 infection. The vaccine is given in two doses, administered 21 days apart.
The FDA's approval of the Pfizer-BioNTech COVID-19 vaccine was based on rigorous scientific research and data from clinical trials that demonstrated the vaccine's safety and efficacy. The clinical trials involved tens of thousands of participants from diverse backgrounds and ages, ensuring that the vaccine was thoroughly tested before being approved for public use.
Since its initial approval in 2020, the Pfizer-BioNTech COVID-19 vaccine has undergone continuous evaluation and monitoring by the FDA to ensure its safety and effectiveness. The FDA has worked closely with the manufacturers and other health organizations to collect and analyze data on the vaccine's performance, including its ability to protect against new variants of the virus.
In 2023, the FDA approved updated versions of the Pfizer-BioNTech COVID-19 vaccine, which are designed to target the variants that are currently circulating. These updated vaccines are available in pharmacies and doctors' offices across the United States, offering continued protection against COVID-19 infection and its severe consequences, including hospitalization and death.
Immunological Memory: What's the Truth?
You may want to see also
Explore related products
$18.99 $18.99
The Moderna vaccine was granted EUA approval by the FDA in 2020
The Moderna vaccine was granted Emergency Use Authorization (EUA) approval by the FDA in 2020. The vaccine was found to be 94.1% effective in clinical studies, and the FDA believed that its potential benefits outweighed the potential risks. The Moderna vaccine is an mRNA vaccine, and it requires two doses, with the recommended interval between doses being one month. However, this is not equivalent to full FDA approval, and the EUA was granted due to the public health emergency caused by the COVID-19 pandemic.
The Moderna vaccine was designed and developed in mid-January 2020, and it received EUA approval from the FDA on December 18, 2020, with distribution beginning on December 21, 2020. This approval came about a week after the FDA granted its first COVID-19 vaccine EUA to Pfizer and BioNTech. The Moderna vaccine has been deemed safe and effective by experts, and it is one of the three widely available COVID-19 vaccines in the US, along with the Pfizer-BioNTech and Johnson & Johnson vaccines.
As of 2023, updated versions of the Moderna and Pfizer-BioNTech vaccines have been approved by the FDA, addressing the variants currently circulating. These updated vaccines are available in pharmacies and doctors' offices across the country. The Moderna vaccine is also one of the vaccines recommended for children, specifically those with one or more health conditions.
The federal government covers the medication costs for the Moderna vaccine under the Affordable Care Act (ACA), and the vaccine must be provided with a $0 copayment. However, the administration costs of the vaccine are covered separately and have been set at $16.94 for the first dose and $28.39 for the second. Due to limited supplies, distribution and administration of the vaccine are managed by state and local healthcare agencies.
Religious Exemption for Vaccines: Illinois' Legal Requirements
You may want to see also
Explore related products
The FDA approved updated COVID-19 vaccines in 2024
The US Food and Drug Administration (FDA) approved updated COVID-19 vaccines in 2024, aiming to provide better protection against circulating variants of the virus. The approved vaccines included the Moderna COVID-19 Vaccine (2024-2025 Formula) for individuals aged 6 months to 11 years and the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) for individuals aged 12 years and older.
The updated vaccines were designed to target the variants that were circulating at the time, ensuring ongoing protection against the serious consequences of COVID-19, including hospitalization and death. Health officials recommended that everyone aged 6 months and older receive one of the updated vaccines, with a minimum gap of two months from their last COVID-19 vaccine dose.
The 2024 approvals built on the FDA's previous authorizations of COVID-19 vaccines. Initially, the FDA granted Emergency Use Authorization (EUA) for vaccines such as Pfizer-BioNTech and Moderna in 2020, followed by Novavax in 2022. These early authorizations played a crucial role in making vaccines accessible during the pandemic.
However, the approval process for COVID-19 vaccines has faced some scrutiny. In 2025, there was uncertainty surrounding the Novavax COVID-19 vaccine due to the Trump administration's imposition of new requirements. This sparked concerns about potential political interference in the FDA's decision-making process, as federal law mandates that the FDA follows established procedures when issuing requirements for drug approval.
The TDAP Vaccine: Late 70's Children and Their Immunization
You may want to see also
Explore related products
$11.93 $21.99
The Novavax COVID-19 vaccine was approved by the FDA in 2024
The Novavax vaccine is a traditional vaccine, and its technology has been used in vaccines to prevent other conditions such as shingles, human papillomavirus, and DTaP (diphtheria, tetanus, and pertussis). The FDA approved the Novavax vaccine for individuals 65 years and older and those aged 12 through 64 with at least one underlying health condition that increases their risk of severe outcomes from COVID-19.
The Novavax vaccine is a protein-based vaccine that uses recombinant nanoparticle technology to create copies of the surface spike protein of SARS-CoV-2, priming the immune system to recognize and fight the virus. Novavax's Matrix-M adjuvant enhances and broadens the immune response. The vaccine is packaged as a ready-to-use liquid formulation and can be stored at standard refrigerator temperatures, making it convenient for distribution through existing vaccine supply channels.
The approval of the Novavax COVID-19 vaccine by the FDA in 2024 provided another important tool in the fight against the pandemic, offering protection to a wider range of individuals, particularly those at high risk of severe disease.
Rabies Vaccine Preparation: Exploring Alternative Methods
You may want to see also
Explore related products
The FDA might not renew the EUA for Pfizer's COVID-19 vaccine for young kids
The US Food and Drug Administration (FDA) has indicated that it may not renew the emergency use authorization (EUA) for Pfizer's COVID-19 vaccine for children aged between six months and four years. This decision would limit the availability of COVID-19 vaccines for the youngest children, as the Pfizer vaccine is currently the only one approved for this age group in the US market.
Pfizer first received the EUA for its vaccine in this age group in June 2022, but uptake has been low. According to the Centers for Disease Control and Prevention (CDC), only 5.6% of children in this age range are vaccinated against COVID-19. While older adults have the highest rates of hospitalization and death from COVID-19, children continue to be hospitalized at rates similar to those seen in 2020 and 2021.
The CDC is in discussions with Moderna to rapidly increase its vaccine supply for young children and ensure sufficient volume and timing. Moderna's COVID-19 vaccine is currently approved for children with one or more health conditions, while Novavax's vaccine is cleared for those aged 12 and older. However, the FDA has not yet approved the formulation for the 2025-2026 season, which may create challenges in vaccine access for young children.
Pfizer has requested that the EUA for its pediatric COVID-19 vaccine remain in place for the upcoming season, emphasizing that deliberations are not related to safety or efficacy concerns. Advocates for vaccine access argue that removing a proven and safe vaccine option for vulnerable children is unacceptable. The potential impact of this decision on children's health and the ongoing pandemic remains a subject of discussion and concern among health authorities and experts.
Actively Acquired Specific Immunity: Understanding the Options
You may want to see also
Frequently asked questions
The FDA has approved vaccines from Pfizer-BioNTech, Moderna, Novavax, and Comirnaty.
The FDA granted an Emergency Use Authorization (EUA) for the Pfizer-BioNTech vaccine on December 11, 2020.
The Novavax vaccine is the only traditional protein-based option for the coronavirus in the US. However, the FDA has not granted full approval yet.
